CY1123105T1 - Μεθοδος για την παρασκευη ανταγωνιστων ανδρογονικων υποδοχεων και ενδιαμεσων αυτων - Google Patents
Μεθοδος για την παρασκευη ανταγωνιστων ανδρογονικων υποδοχεων και ενδιαμεσων αυτωνInfo
- Publication number
- CY1123105T1 CY1123105T1 CY20201100495T CY201100495T CY1123105T1 CY 1123105 T1 CY1123105 T1 CY 1123105T1 CY 20201100495 T CY20201100495 T CY 20201100495T CY 201100495 T CY201100495 T CY 201100495T CY 1123105 T1 CY1123105 T1 CY 1123105T1
- Authority
- CY
- Cyprus
- Prior art keywords
- preparation
- androgen receptor
- intermediates
- pyrazol
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Η παρούσα εφεύρεση αφορά μια βελτιωμένη μέθοδο για την παρασκευή ανταγωνιστών ανδρογονικών υποδοχέων (AR) δομημένων με καρβοξαμίδιο όπως το Ν-((S)-1-(3-(3-χλωρο-4-κυανοφαινυλο)-1Η-πυραζολο-1 -υλο)-προπανο-2-υλο)-5-( 1 -υδροξυαιθυλο)-1Η-πυραζόλιο-3-καρβοξαμίδιο (1Α) και βασικών ενδιάμεσων αυτών όπως το 2-χλωρο-4-(1Η-πυραζολο-3-υλο) βενζονιτρίλιο (V). Οι ανταγωνιστές των AR είναι χρήσιμοι στη θεραπευτική αντιμετώπιση του καρκίνου, ιδιαίτερα του καρκίνου του προστάτη και άλλων νόσων όπου είναι επιθυμητός ο ανταγωνισμός με τους AR.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20150111 | 2015-04-09 | ||
| PCT/FI2016/050220 WO2016162604A1 (en) | 2015-04-09 | 2016-04-08 | Process for the preparation of androgen receptor antagonists and intermediates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123105T1 true CY1123105T1 (el) | 2021-10-29 |
Family
ID=55802393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100495T CY1123105T1 (el) | 2015-04-09 | 2020-05-25 | Μεθοδος για την παρασκευη ανταγωνιστων ανδρογονικων υποδοχεων και ενδιαμεσων αυτων |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10189789B2 (el) |
| EP (1) | EP3280710B1 (el) |
| JP (1) | JP6707560B2 (el) |
| KR (1) | KR102628078B1 (el) |
| CN (1) | CN107428695B (el) |
| AU (1) | AU2016245278B2 (el) |
| BR (1) | BR112017021636B1 (el) |
| CA (1) | CA2980965C (el) |
| CL (2) | CL2017002491A1 (el) |
| CO (1) | CO2017010052A2 (el) |
| CY (1) | CY1123105T1 (el) |
| DK (1) | DK3280710T3 (el) |
| ES (1) | ES2800828T3 (el) |
| HK (1) | HK1250710A1 (el) |
| HR (1) | HRP20200707T1 (el) |
| HU (1) | HUE049144T2 (el) |
| IL (1) | IL254629B (el) |
| LT (1) | LT3280710T (el) |
| MX (1) | MX2017012910A (el) |
| MY (1) | MY185488A (el) |
| PE (1) | PE20171738A1 (el) |
| PL (1) | PL3280710T3 (el) |
| PT (1) | PT3280710T (el) |
| RS (1) | RS60184B1 (el) |
| RU (1) | RU2719590C2 (el) |
| SG (1) | SG11201707959VA (el) |
| SI (1) | SI3280710T1 (el) |
| UA (1) | UA120777C2 (el) |
| WO (1) | WO2016162604A1 (el) |
| ZA (1) | ZA201706671B (el) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019121509A1 (en) * | 2017-12-19 | 2019-06-27 | Boehringer Ingelheim Vetmedica Gmbh | Synthesis of the 1 :1 :1 co-crystal of 1 -cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1 -yl)-benzene, l-proline and water |
| US11236070B2 (en) | 2019-05-16 | 2022-02-01 | Novartis Ag | Chemical process |
| EP3993779A1 (en) | 2019-07-02 | 2022-05-11 | Orion Corporation | Pharmaceutical composition of darolutamide |
| CN110590668A (zh) * | 2019-07-17 | 2019-12-20 | 江苏君若医药有限公司 | N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法 |
| CN110483534B (zh) * | 2019-07-23 | 2021-05-18 | 上海药明康德新药开发有限公司 | 一种(2,4,5,7-四氢吡喃并[3,4-c]吡唑-7-基)甲醇的制备方法 |
| CN111116476A (zh) * | 2019-12-27 | 2020-05-08 | 武汉九州钰民医药科技有限公司 | 制备抗肿瘤药物多拉米胺的方法 |
| CN111116477B (zh) * | 2019-12-27 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | 多拉米胺的合成工艺 |
| JP2023528200A (ja) | 2020-05-11 | 2023-07-04 | オリオン コーポレーション | アンドロゲン受容体アンタゴニストおよびその中間体の製造方法 |
| CN113527208A (zh) * | 2021-08-31 | 2021-10-22 | 江西金丰药业有限公司 | 一步法制备2-氯-4-（1h-吡唑-3-基）苯甲腈的方法 |
| CN113861115A (zh) * | 2021-09-10 | 2021-12-31 | 浙江师范大学 | 一种吡唑酰胺类衍生物及合成方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| EP2699561B1 (en) * | 2011-04-21 | 2015-06-03 | Orion Corporation | Androgen receptor modulating carboxamides |
| BR112013028666A2 (pt) * | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
-
2016
- 2016-04-08 SG SG11201707959VA patent/SG11201707959VA/en unknown
- 2016-04-08 DK DK16717672.6T patent/DK3280710T3/da active
- 2016-04-08 MX MX2017012910A patent/MX2017012910A/es unknown
- 2016-04-08 EP EP16717672.6A patent/EP3280710B1/en active Active
- 2016-04-08 RS RS20200496A patent/RS60184B1/sr unknown
- 2016-04-08 PT PT167176726T patent/PT3280710T/pt unknown
- 2016-04-08 RU RU2017134662A patent/RU2719590C2/ru not_active Application Discontinuation
- 2016-04-08 US US15/564,878 patent/US10189789B2/en active Active
- 2016-04-08 KR KR1020177032529A patent/KR102628078B1/ko active IP Right Grant
- 2016-04-08 PL PL16717672T patent/PL3280710T3/pl unknown
- 2016-04-08 PE PE2017001969A patent/PE20171738A1/es unknown
- 2016-04-08 HU HUE16717672A patent/HUE049144T2/hu unknown
- 2016-04-08 ES ES16717672T patent/ES2800828T3/es active Active
- 2016-04-08 BR BR112017021636-1A patent/BR112017021636B1/pt active IP Right Grant
- 2016-04-08 SI SI201630674T patent/SI3280710T1/sl unknown
- 2016-04-08 MY MYPI2017703709A patent/MY185488A/en unknown
- 2016-04-08 LT LTEP16717672.6T patent/LT3280710T/lt unknown
- 2016-04-08 AU AU2016245278A patent/AU2016245278B2/en active Active
- 2016-04-08 WO PCT/FI2016/050220 patent/WO2016162604A1/en active Application Filing
- 2016-04-08 CN CN201680018881.7A patent/CN107428695B/zh active Active
- 2016-04-08 CA CA2980965A patent/CA2980965C/en active Active
- 2016-04-08 JP JP2017552929A patent/JP6707560B2/ja active Active
- 2016-04-08 UA UAA201710897A patent/UA120777C2/uk unknown
-
2017
- 2017-09-24 IL IL254629A patent/IL254629B/en active IP Right Grant
- 2017-10-03 CL CL2017002491A patent/CL2017002491A1/es unknown
- 2017-10-03 CO CONC2017/0010052A patent/CO2017010052A2/es unknown
- 2017-10-04 ZA ZA2017/06671A patent/ZA201706671B/en unknown
-
2018
- 2018-08-06 HK HK18110069.5A patent/HK1250710A1/zh unknown
-
2019
- 2019-02-14 CL CL2019000397A patent/CL2019000397A1/es unknown
-
2020
- 2020-05-04 HR HRP20200707TT patent/HRP20200707T1/hr unknown
- 2020-05-25 CY CY20201100495T patent/CY1123105T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123105T1 (el) | Μεθοδος για την παρασκευη ανταγωνιστων ανδρογονικων υποδοχεων και ενδιαμεσων αυτων | |
| CY1121395T1 (el) | Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6 | |
| CL2017003226A1 (es) | Reguladores nrf2 | |
| EA201891397A1 (ru) | Твердые фармацевтические композиции антагонистов рецепторов андрогенов | |
| CY1118143T1 (el) | Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1 | |
| CR20190071A (es) | Compuestos, composiciones y métodos para el tratamiento de enfermedades | |
| PH12016500358A1 (en) | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof | |
| EA201792536A1 (ru) | Триазоловые агонисты рецептора apj | |
| WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
| EA201691853A1 (ru) | Агонисты мускариновых рецепторов | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| CY1123031T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| CY1123231T1 (el) | Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο | |
| CY1121187T1 (el) | Ενα εκχυλισμα απο indigo naturalis και μια διεργασια για την παρασκευη εκεινου | |
| NZ724870A (en) | Antibodies that bind human cannabinoid 1 (cb1) receptor | |
| CY1124381T1 (el) | Παραγωγα οξαδιαζολοπυριδινης για χρηση ως αναστολεις της ο-ακυλο τρανσφερασης της γκρελινης | |
| CL2016002839A1 (es) | Derivados de carboxamida | |
| TN2019000106A1 (en) | Novel compounds for treating parasitic disease | |
| EA201791249A1 (ru) | Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний | |
| CO2018004569A2 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| CY1121624T1 (el) | Παραγωγα 2-αρυλο-4-υδροξυ-1,3-θειαζολιου χρησιμα ως αναστολεις trpm8 για τη θεραπεια της νευραλγιας, του πονου, της χαπ και του ασθματος | |
| CY1125297T1 (el) | Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια | |
| IN2015CH01182A (el) |